Prognostic significance of serum ca 125 antigen assay in patients with non-small cell lung cancer

Abstract

Background. The serum levels of CA 125 tumor‐associated antigen in patients with lung cancer have been previously related to TNM stage, histologic type, and survival rate. In the current study, the prognostic information provided by the CA 125 antigen assay was analyzed. Methods. Preoperative serum of CA 125 antigen was determined in 137 patients with non‐small cell lung cancer. The assay was performed by means of a solidphase enzyme‐immunoassay test. The influence of CA 125 serum level on postoperative outcome was studied by a multivariate analysis, performed with Cox's proportional hazards regression model. Results. Patients whose initial CA 125 level was higher than 15 U/ml had a 3.25‐fold greater likelihood of relapse (95% confidence interval [CI], 1.7–6.21) (P < 0.001) and a 4.27‐fold greater likelihood of death (95% CI, 2.42–7.55) (P < 0.001) due to cancer than patients with lower values. For patients with serum levels over 15 U/ml, the 36‐month survival rate posttreatment was lower (67% versus 20%) (P < 0.001), as was the disease‐free rate (64% versus 13%) (P < 0.001). After adjustment for TNM stages, histologic type, sex, and age, patients with CA 125 values over 15 U/ml continued exhibiting higher risk of relapse (hazard ratio, 2.2; 95% CI, 1.04–4.69) (P = 0.04) and higher risk of death (hazard ratio, 2.42; 95% CI, 1.29–4.54) (P = 0.006). Conclusions. CA 125 is an independent prognostic factor of survival and tumor relapse in non‐small cell lung cancer. The preoperative serum level of CA 125 antigen is inversely correlated with the outcome figures. The authors suggest that CA 125 be included in any future multifactorial analysis of survival. Cancer 1994; 73:1368–76.

Diagnostic Value of Preoperative Serum Carcinoembryonic Antigen and Carbohydrate Antigen 19-9 in Colorectal Cancer

“…The association of ca 19-9 with prognosis was found to be better than that of cea [16][17][18] . In contrast, other publications have reported that the use of ca 19-9 is limited.…”

CA-125 requisition pattern in a tertiary care hospital in central India and necessary modifications

“…10,11 Clinical utility of CA-125 is thus well known but not limited to epithelial ovarian cancer with elevated levels being also associated with malignancies of endometrium, cervix, lung, breast, liver and in gastric, pancreatic, colorectal malignancies. [12][13][14] Owing to its origin from multiple epithelium of multiple tissues viz. amnion, fetal coelomic epithelium, fallopian tube epithelium and in many adult tissues, including endometrium, endocervix, pleura or peritoneum; it is amenable to elevation in benign inflammatory conditions of these epithelium and in case of structural breach.…”

Prediction of survival and recurrence by serum and cytosolic levels of CEA, CA125 and SCC antigens in resectable non-small-cell lung cancer

“…CA125 was initially described as an ovarian cancer-associated antigen, and has recently been assayed in NSCLC. In a previous study we reported that serum levels of CA 125 provide independent information on survival and tumour relapse in patients undergoing curative surgical treatment for NSCLC (Diez et al, 1994a).…”

“…CA125 was initially described as an ovarian cancer-associated antigen, and has recently been assayed in NSCLC. In a previous study we reported that serum levels of CA 125 provide independent information on survival and tumour relapse in patients undergoing curative surgical treatment for NSCLC (Diez et al, 1994a Analysis of tumour marker expression in NSCLC tumour tissue has not been reported as frequently. In a previous study we observed that cytosolic concentration of CEA, SCC and CA125 is a particular and distinctive characteristic of each histological type, something which could aid pathological classification (Picardo et al, 1994).…”